PathAI icharatidza kufambira mberi kwazvino mukushandiswa kweAI-based pathology

PathaI, mutungamiri wepasi rose mune tekinoroji yakavakirwaArtificial Intelligence (AI) yePathology, nhasi yazivisa kuti tsvagiridzo yesangano ichangoburwa ichaunzwa pamusangano unouya we2022 AASLD 2022 Liver Meeting*, uri kuitika muWashington, DC Mbudzi 4-8, 2022.

Pachiitiko chegore rino, PathAI ichagovera huwandu hwemharidzo shanu, zviratidziro zvina uye mharidzo imwe yemuromo, ina dzacho dzakagadzirwa pamwe chete nevadyi vemishonga. Kunyanya, zvitsva zvakawanikwa zve nonalcoholic steatohepatitis (NASH) zvinosimbisa kuti PathAI inoenderera mberi sei kugadzirisa kudiwa kweiyo inodhindwa uye yakaringana Clinical Research Network (CRN) yekukoira chishandiso kuti isangane nemiyero yemazuva ano eNASH miedzo yekiriniki, pamwe nekudiwa kwezvimwe. robust quantitative data zviyero.

"Tsvakurudzo yazvino yechikwata chedu ine chinangwa chekuongorora kusiyanisa kuripo mukuongororwa kwehutachiona hwechiropa biopsies. Zvatinowana zvinoratidza kuti kubatanidza mhinduro dzeAI mukuita uku kunogona kuvandudza zvakanyanya kuenderana uye kurongeka kweongororo idzi, "akadaro Dr. Mike Montalto, Chief Scientific Officer wePathaI. "Iyi nzira inozowedzera mukuvandudza kuvandudzwa kwezvinodhaka zveNASH, izvo zvakakosha pakugadzirisa dambudziko rakakura rekurapa kuvarwere."

Muhurukuro yemuromo yakagadzirwa nekubatana neGiriyedhi Sayenzi,  "Ongororo yekuongorora yeNASH histology uchishandisa CRN zvibodzwa zvakatorwa kubva kune yakawanda-yakasvibisa nzira yekudzidza muchina", PathAI icharatidza mutsva wekudzidza muchina (ML)-based scoring modhi, inoshandisa yakasanganiswa ruzivo kubva kuH&E uye Masson tri-ruvara mifananidzo kufanotaura NASH CRN mamakisi/matanho. Ikozvino maitiro ekuongorora maNASH biopsies ari pasi pekusiyana kwepamusoro; Tsvagiridzo iyi inoratidza kuti PathAI ML inogona kusanganisa ruzivo rwe histological kubva kune akawanda akazara masiraidhi mifananidzo kufanotaura NASH CRN mamakisi/matanho pamwero unoenderera, zvichigona kudzikisira mutsauko pakati petishu sampuli yakaongororwa kune yega yega. Uyezve, iyo inoenderera mberi yeCRN inoratidzira zvibodzwa zvakatorwa kubva kune izvi zvakafanotaurwa zvakatorwa kubva kune imwechete yekuisa; sekudaro, iyo PathAI modhi inobvumira kuenzaniswa kwakananga kwezvinhu zvine chekuita neayo mana histological maficha eNASH,

Kuenderera mberi nekuratidza kushanda kwePathAI yekuenderera mberi kweML scoring kugona, PathAI icharatidza data rakagadzirwa nekubatana neNovo Nordisk inoratidza kuti chiropa histology ongororo yaiwanzoenderana kune vese pathologists uye ML ongororo muvarwere vane NASH cirrhosis. "Kuenzanisa kweSemaglutide Migumisiro paChiropa Histology muVarwere Vane Nonalcoholic Steatohepatitis Cirrhosis Pakati PeMashini Kudzidza Model Assessment uye Pathologist Assessment,"  inotaura kuti PathAI's ML ongororo yakawana vanopindura placebo vashoma pane zvibodzwa zvevarwere, zvichitsigira zvakambotaurwa zvakaonekwa uye zvichipa humwe humbowo hwekuti nzira dzeML dzinogona kunyatsotora mhinduro yekurapa mumakiriniki ekuedzwa paNASH.

PathaI inoenderera mberi nekufambisira mberi tsvagiridzo yeNASH kutsigira kudiwa kwenguva refu kwekuwedzera kuongororwa kwechiropa biopsies. Kupa nzira itsva mu” Quantitative multimodal anisotropy imaging inogonesa muchina kudzidza kufanotaura kweCRN NASH fibrosis nhanho pasina bhuku rondedzero. ", PathaI inogadzirisa kusiyanisa kwechinyorwa pathologic staging ye fibrosis muNASH ichishandisa huwandu hwakawanda-modhi anisotropy imaging (QMAI) yefibrosis kupa zvirevo zvisina tsarukano kudzidzisa mamodeli kufanotaura NASH CRN fibrosis nhanho mune zvimwe zvikamu zvetishu. Nekuenzanisa mashandiro emuenzaniso nechibodzwa chechiremba, mamodheru aya akafanotaura CRN fibrosis nhanho nekunyatso kuenzaniswa nemamodheru akadzidziswa neanathologist rondedzero yeMT-yakasvibiswa tishu zvikamu.

BlogInnovazione.it

​